Synthesis and characterization of novel strong electron acceptors: bithiazole analogues of tetracyanodiphenoquinodimethane (TCNDQ)
摘要:
Novel electron accepters, bithiazole analogues of tetracyanodiphenoquinodimethane (TCNDQ), were synthesized by using a Pd-catalyzed coupling reaction of a dibromated precursor with sodium dicyanomethanide. The new accepters show strong electron-accepting ability and small on-site Coulomb repulsion. The X-ray crystallographic analysis has revealed a planar structure containing a double bond with E-configuration. Several charge transfer complexes were obtained with electron donors such as tetrathiafulvalene (TTF), (C) 2000 Elsevier Science Ltd. All rights reserved.
ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
申请人:AMARI Gabriele
公开号:US20110311461A1
公开(公告)日:2011-12-22
The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.
Method for preparing largazole analogs and uses thereof
申请人:Williams Robert M.
公开号:US20100029731A1
公开(公告)日:2010-02-04
Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
Sulfonamide lactams of the following formula
wherein X, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R7 and R8 are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2011060000A1
公开(公告)日:2011-05-19
This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.